Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Liver Cirrhosis

In brief

This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.

Key facts

Study ID: NCT05516498
Run by: AstraZeneca
People needed: 205
Starts: 2022-10-31
Expected to finish: 2025-07-17
Last updated by the study team: 2025-08-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Research Site — Birmingham, Alabama, United States
Research Site — Pasadena, California, United States
Research Site — San Francisco, California, United States
Research Site — West Hollywood, California, United States
Research Site — Rochester, Minnesota, United States
Research Site — The Bronx, New York, United States
Research Site — Charleston, South Carolina, United States
Research Site — Dallas, Texas, United States
Research Site — Charlottesville, Virginia, United States
Research Site — Richmond, Virginia, United States
Research Site — Milwaukee, Wisconsin, United States
Research Site — Heidelberg, Australia
Research Site — Vienna, Austria
Research Site — Edegem, Belgium
Research Site — Beijing, China
Research Site — Chengdu, China
Research Site — Guangzhou, China
Research Site — Hangzhou, China
Research Site — Prague, Czechia
Research Site — Prague, Czechia
Research Site — Aarhus N, Denmark
Research Site — Esbjerg, Denmark
Research Site — Hvidovre, Denmark
Research Site — Køge, Denmark
Research Site — Angers, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.